The HCV care continuum among people who use drugs: Protocol for a systematic review and meta-analysis

Jennifer R. Reed, Ashly E. Jordan, David C. Perlman, Daniel J. Smith, Holly Hagan

Research output: Contribution to journalArticle

Abstract

Introduction: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the "HCV care continuum") have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD. Methods/design: Scientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis. Discussion: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD. Systematic review registration: PROSPERO CRD42016034113

Original languageEnglish (US)
Article number110
JournalSystematic Reviews
Volume5
Issue number1
DOIs
StatePublished - Jul 11 2016

Fingerprint

Continuity of Patient Care
Hepacivirus
Meta-Analysis
Pharmaceutical Preparations
Virus Diseases
Selection Bias
Therapeutics

Keywords

  • Healthcare access
  • Hepatitis c
  • Hepatitis c care continuum
  • Meta-analysis
  • People who use drugs
  • Systematic review

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

The HCV care continuum among people who use drugs : Protocol for a systematic review and meta-analysis. / Reed, Jennifer R.; Jordan, Ashly E.; Perlman, David C.; Smith, Daniel J.; Hagan, Holly.

In: Systematic Reviews, Vol. 5, No. 1, 110, 11.07.2016.

Research output: Contribution to journalArticle

Reed, Jennifer R. ; Jordan, Ashly E. ; Perlman, David C. ; Smith, Daniel J. ; Hagan, Holly. / The HCV care continuum among people who use drugs : Protocol for a systematic review and meta-analysis. In: Systematic Reviews. 2016 ; Vol. 5, No. 1.
@article{cfb3ecfd85dd414cb4e6c803faa37e80,
title = "The HCV care continuum among people who use drugs: Protocol for a systematic review and meta-analysis",
abstract = "Introduction: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the {"}HCV care continuum{"}) have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 {\%}, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD. Methods/design: Scientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis. Discussion: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD. Systematic review registration: PROSPERO CRD42016034113",
keywords = "Healthcare access, Hepatitis c, Hepatitis c care continuum, Meta-analysis, People who use drugs, Systematic review",
author = "Reed, {Jennifer R.} and Jordan, {Ashly E.} and Perlman, {David C.} and Smith, {Daniel J.} and Holly Hagan",
year = "2016",
month = "7",
day = "11",
doi = "10.1186/s13643-016-0293-6",
language = "English (US)",
volume = "5",
journal = "Systematic Reviews",
issn = "2046-4053",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The HCV care continuum among people who use drugs

T2 - Protocol for a systematic review and meta-analysis

AU - Reed, Jennifer R.

AU - Jordan, Ashly E.

AU - Perlman, David C.

AU - Smith, Daniel J.

AU - Hagan, Holly

PY - 2016/7/11

Y1 - 2016/7/11

N2 - Introduction: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the "HCV care continuum") have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD. Methods/design: Scientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis. Discussion: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD. Systematic review registration: PROSPERO CRD42016034113

AB - Introduction: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the "HCV care continuum") have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low compared to other populations. Delineating the progression of PWUD through the steps in the HCV care continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD. Methods/design: Scientific databases will be searched using a comprehensive automated search strategy; gray literature and reference lists will be manually searched. Eligible reports will provide original research data related to the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps: screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be developed to assess the extent to which an included report reflects an effectiveness or efficacy study design. Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity will be assessed at each stage of data synthesis. Discussion: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used to inform policy to directly improve HCV care for PWUD. Systematic review registration: PROSPERO CRD42016034113

KW - Healthcare access

KW - Hepatitis c

KW - Hepatitis c care continuum

KW - Meta-analysis

KW - People who use drugs

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84977622656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977622656&partnerID=8YFLogxK

U2 - 10.1186/s13643-016-0293-6

DO - 10.1186/s13643-016-0293-6

M3 - Article

C2 - 27401499

AN - SCOPUS:84977622656

VL - 5

JO - Systematic Reviews

JF - Systematic Reviews

SN - 2046-4053

IS - 1

M1 - 110

ER -